TABLE 2.
Clinical Characteristics During Study Period Reported by Patients at Follow-up
| Variable | Value, % |
|---|---|
| Rheumatic disease flares | |
| None | 37 |
| Typical | 40 |
| Worse | 23 |
| Rheumatic disease activity | |
| Typical | 35 |
| More active | 31 |
| Less active | 24 |
| Unpredictable | 9 |
| Medications modified due to pandemic | 11 |
| Medications compared with enrollment | |
| Same | 45 |
| More prednisonea | 24 |
| Less prednisoneb | 4 |
| More conventional DMARDsa,c | 12 |
| Less conventional DMARDsb,c | 8 |
| More biologic DMARDsa | 22 |
| Less biological DMARDsb | 5 |
| Satisfaction with management of rheumatic disease medications | |
| Very satisfied | 44 |
| Satisfied | 27 |
| Neutral | 17 |
| Dissatisfied | 9 |
| Very dissatisfied | 3 |
| Current status of rheumatic disease | |
| Excellent | 11 |
| Very good | 22 |
| Good | 41 |
| Fair | 21 |
| Poor | 6 |
| New major physical or mental health diagnosis | 14 |
aIncludes increased dose and more frequent dosing interval.
bIncludes lower dose and less frequent dosing interval.
cNot including prednisone.